Compare · CSTL vs ELV
CSTL vs ELV
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $87.75B, about 139.8x CSTL ($627.8M).
- Over the past year, CSTL is up 7.3% and ELV is up 7.2% - CSTL leads by 0.1 points.
- CSTL has been more active in the news (18 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 5 for CSTL).
- Company
- Castle Biosciences Inc.
- Elevance Health Inc.
- Price
- $20.68-1.43%
- $403.85+1.16%
- Market cap
- $627.8M
- $87.75B
- 1M return
- +14.13%
- +1.01%
- 1Y return
- +7.32%
- +7.24%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 18
- 3
- Recent ratings
- 5
- 23
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CSTL
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $205,149 worth of shares (9,836 units at $20.86) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 4 filed by Director Olson Tiffany
- SEC Form 4 filed by Director Goldberg Ellen
- SEC Form 4 filed by Director Harrison Miles
- SEC Form 4 filed by Director Cotton Rodney
- SEC Form 4 filed by Director Caple Kim
- SEC Form 4 filed by Director Bradbury Daniel
- SEC Form 4 filed by Director Cole G Bradley
- Castle Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest ELV
- Director Dixon Robert L Jr sold $60,667 worth of shares (151 units at $401.77), decreasing direct ownership by 1% to 10,734 units (SEC Form 4)
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)